EZSCAN is a revolutionary device for screening and assessment of cardiometabolic risk.
EZSCAN is non invasive and provides immediate results, without any need for patient preparation, fasting or blood drawing. Findings are available following a simple 2 minute test. EZSCAN is therefore perfectly suited for general practitioners, pharmacists, cardiologists and neuroplogists.
Reliable screening test
Recent clinical studies have shown EZSCAN to be highly accurate and re-
producible in head to head comparisons with conventional blood tests.
ESC values measured by EZSCAN had a sensitivity of 75% and a specificity of 100% with an area under the ROC curve of 0.88 . Coefficients of variation on hand and foot measurements were 7% and 5% respectively.
Its good sensitivity, specificity and reproducibility make EZSCAN a reliable tool to assess sudomotor dysfunction, a clinical manifestation of autonomic neuropathy in patients with cardiometabolic risk.  
EZSCAN and cardiorespiratory fitness level
A recent study showed that sudomotor dysfunction as assessed by EZSCAN is correlated to cardio-respiratory fitness levels measured by VO2max. The correlation between sudomotor function score and VO2max was r=0.57, p<0.0001 (women) (figure 6) and 0.48, p<0.0001 (men). EZSCAN can be used to assess CVD or metabolic disease risk early and for follow-up of an individual’s preventive interventions .
 Schwarz at al. EZSCAN, a new technology to detect diabetes risk . Br J Diabetes Vasc Dis. 2011;11(4):204-209  Mayaudon et al. A new method for assessing sudomotor function : relevance in type 2 diabetes. Diabetes Metab. 2010;36:450-454  Raisanen et al. Assessment of sudomotor function as a tool for cardiorespiratory fitness level evaluation: comparison with VO2max. Unpublished results